奥希替尼对携带EGFR外显子20插入突变NSCLC的临床前建模研究
研究建立7种EGFR外显子20插入突变Ba/F3模型及1例患者来源NSCLC(SNU-3173),评估第一至三代EGFR酪氨酸激酶抑制剂(TKI)的效力。结果显示多数外显子20插入突变细胞对第一代TKI耐药,对第二代TKI敏感但H773insH例外,奥希替尼对包括H773insH在内的突变细胞高效且不损伤野生型EGFR细胞。
要点
- 除A763insFQEA外,外显子20插入突变NSCLC细胞对第一代EGFR TKI耐药。
- 突变细胞对第二代EGFR TKI敏感,但H773insH突变细胞敏感性较低。
- 奥希替尼对包括H773insH在内的外显子20插入突变细胞高效,且不损伤野生型EGFR细胞。
核心结论
- 奥希替尼在临床前模型中对EGFR外显子20插入突变NSCLC具有活性,并能灵活结合于药物结合口袋。
研究设计与样本
- 研究建立7种EGFR外显子20插入突变Ba/F3模型和1例患者来源NSCLC(SNU-3173),亚型包括A763insFQEA、V769insASV、D770insSVD、D770insNPG、P772insPR、H773insH、H773insNPH和H773insAH。
- 进行细胞活力测定、免疫印迹和N-乙基-N-亚硝基脲诱变筛选。
- 对EGFR外显子20插入突变结构与奥希替尼的结合进行建模和比较。
主要发现
- 除A763insFQEA外,外显子20插入突变NSCLC细胞对第一代EGFR TKI耐药,IC50为1.1 ± 0.067至5.4 ± 0.115 μM。
- 突变细胞对第二代EGFR TKI敏感,IC50为0.02 ± 0.0002至161.8 ± 18.7 nM;但H773insH突变细胞IC50为46.3 ± 8.0至352.5 ± 22.7 nM。
- 第三代EGFR TKI奥希替尼对外显子20插入突变细胞高效,IC50为14.7-62.7 nM,包括H773insH,且不损伤野生型EGFR细胞。
- N-乙基-N-亚硝基脲诱变筛选显示第二突变位点主要位于外显子20和21,包括E762K、P794S和G796D。
- 通过逐步暴露于奥希替尼建立耐药细胞,其携带EGFR E762K突变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: NSCLC with EGFR exon 20 insertion mutations is the third most common type of EGFR-mutant NSCLC and is resistant to EGFR tyrosine kinase inhibitors (TKIs). This study was conducted to evaluate the efficacies of first- to third-generation EGFR TKIs against NSCLC cells harboring EGFR exon 20 insertion mutations. METHODS: We developed seven EGFR exon 20 insertion-mutant Ba/F3 models and one patient-derived NSCLC (SNU-3173) of subtypes A763insFQEA, V769insASV, D770insSVD, D770insNPG, P772insPR, H773insH, H773insNPH, and H773insAH. Cell viability assays, immunoblotting, and N-ethyl-N-nitrosourea mutagenesis screenings were performed. EGFR exon 20 insertion-mutant structures and couplings with osimertinib, a third-generation EGFR TKI, were modeled and compared. RESULTS: EGFR exon 20 insertion-mutant NSCLC cells, excluding EGFR A763insFQEA, were resistant to first-generation EGFR TKIs (concentration that inhibits 50% [IC50], 1.1 ± 0.067 to 5.4 ± 0.115 μM). Mutants were sensitive to second-generation EGFR TKIs (IC50, 0.02 ± 0.0002 to 161.8 ± 18.7nM), except EGFR H773insH (IC50, 46.3 ± 8.0 to 352.5 ± 22.7nM). The IC50 ratios for mutant to wild-type cells were higher than those for third-generation EGFR TKIs. Third-generation EGFR TKI osimertinib was highly potent against EGFR exon 20 insertion-mutant cells (IC50, 14.7-62.7 nM), including EGFR H773insH, and spared wild-type EGFR cells. N-ethyl-N-nitrosourea mutagenesis screening of EGFR exon 20 insertion-mutant Ba/F3 cells showed various second sites for EGFR mutations, mostly at exons 20 and 21, including E762K, P794S, and G796D. In addition, osimertinib-resistant cells were established by stepwise exposure to osimertinib and harbored EGFR E762K mutation. CONCLUSIONS: Osimertinib is active against EGFR exon 20 insertion-mutant NSCLC and flexibly binds within drug-binding pockets in preclinical models.
引用
- Lee Y, Kim TM, Kim DW, et al. Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. J Thorac Oncol. 2019. PMID: 31108249. doi:10.1016/j.jtho.2019.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。